All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Advanced Breast Cancer at Diagnosis Linked to 10% Higher CVD Risk

February 7th 2025

Kevin T. Nead, MD, MPhil, details findings on the association between prevalent CVD and breast cancer and next steps for investigating the connection.

First- and Later-Line Avapritinib Prolongs OS, DOT in Advanced Systemic Mastocytosis

February 7th 2025

Patients with systemic mastocytosis experienced superior OS and DOT outcomes with first- and later-line avapritinib vs midostaurin and BAT, respectively.

FDA Grants Breakthrough Device Designation to Serial CTRS AI Model for NSCLC

February 7th 2025

The FDA has granted breakthrough device designation to Serial CTRS for risk prognosis in non–small cell lung cancer.

MD Anderson Study Resumes With Seclidemstat/Azacitidine in MDS/CMML

February 7th 2025

The combination of seclidemstat and azacitidine will resume study in a phase 1/2 trial in patients with MDS and CMML following a partial clinical hold.

Northwestern Medicine Performs the Highest Number of Lung Transplants in the United States

February 7th 2025

The Canning Thoracic Institute became the highest-volume lung transplant center in the US and achieved the shortest wait time for a lung transplant.

KN026 Plus Docetaxel Demonstrates Efficacy in HER2+ Metastatic Breast Cancer

February 7th 2025

KN026 plus docetaxel elicited durable responses and a manageable safety profile in patients with recurrent/metastatic HER2-positive breast cancer.

Venetoclax Elicits Immune Synapse Repair in Chronic Lymphocytic Leukemia

February 7th 2025

Matthew Cortese, MD, MPH, discusses an evaluation of immunologic changes with the treatment of venetoclax in patients with chronic lymphocytic leukemia.

Envafolimab Plus Suvemcitug and FOLFIRI Shows Early Efficacy, Tolerability in Second-Line CRC

February 7th 2025

Envafolimab plus suvemcitug and FOLFIRI demonstrated preliminary activity and tolerability in second-line MSS/pMMR CRC.

Emerging Data Continue to Shape the Role of Blinatumomab in Acute Lymphoblastic Leukemia

February 6th 2025

Adam Duvall, MD, MPH, spotlights new research further elucidating the role of blinatumomab in the acute lymphoblastic leukemia treatment paradigm.

NX-5948 Demonstrates Preliminary Efficacy in High-Risk CLL

February 6th 2025

Alvaro Alencar, MD, discusses the preliminary efficacy and safety of NX-5948, a BTK degrader, in patients with chronic lymphocytic leukemia.

ATG-022 Demonstrates Safety, Preliminary Efficacy in Advanced CLDN18.2+ Gastric Cancer

February 6th 2025

Phase 1 study data demonstrated that ATG-022 has a manageable safety profile and produced activity in patients with gastric cancer and CLDN 18.2 expressions.

Yale Medicine Takes Top Spots in National, State Rankings

February 6th 2025

Yale Medicine was ranked third in the nation for physician practices, an annual designation by Castle Connolly.

Ziftomenib Meets CR/CRh End Point in R/R NPM1+ AML

February 6th 2025

The oral menin inhibitor ziftomenib produced responses in patients with relapsed/refractory NPM1-mutant AML.

FDA Grants Orphan Drug Designation to 225Ac-Satoreotide for SCLC

February 6th 2025

The FDA has granted orphan drug designation to 225Ac-satoreotide for patients with small cell lung cancer.

AI-Enabled Chatbot Replicates Efficacy of SOC Approaches in Aiding Receipt of Cancer Genetic Testing

February 6th 2025

A chatbot-based approach was equivalent to SOC pretest cancer genetic services and genetic testing among individuals eligible for cancer genetic testing.

Eribulin Proves Noninferior to Taxane as Combination Partner With Trastuzumab and Pertuzumab in HER2+ Breast Cancer

February 6th 2025

Adding eribulin to trastuzumab/pertuzumab rather than taxane resulted in a numerically longer median time to QOL deterioration and similar efficacy outcomes in HER2+ breast cancer.

Case Closed: Experts Piece Together the Top Takeaways From the 2025 Gastrointestinal Cancers Symposium

February 6th 2025

Get the inside scoop from Drs Lou, Patel, and Beg on the top takeaways to come out of the 2025 Gastrointestinal Cancers Symposium.

Gemogenovatucel-T Receives FDA RMAT Designation for Advanced HRP Ovarian Cancer

February 5th 2025

The FDA granted RMAT designation to gemogenovatucel-T for maintenance treatment after frontline chemotherapy in advanced HRP ovarian cancer.

Transforming Cancer Care Through Data: How Texas Colon & Rectal Specialists Enhances Outcomes, Experiences, and Efficiency

February 5th 2025

How Texas Colon & Rectal Specialists enhance outcomes, experiences, and efficiency data-driven care to improve patient outcome.

Beyond TKIs: Synthetic Lethal Approaches and Targeted Therapies to Watch in Lung Cancer

February 5th 2025

Leveraging synthetic lethal approaches in lung cancer with new targets and agents may be a promising avenue of investigation.